Articles

CBA Members

Intellectual
Property

CBA Intellectual Property Section

Articles are published by the Intellectual Property Section. Members interested in posting articles are encouraged to send them to the Section by email: CBAI_P@cba.org.

Today
Today

Case summary: Court rejects argument that plaintiffs’ counsel cannot object on examination for discovery to improper questions asked of non-party inventors

  • November 01, 2023
  • David Schnittker

The Defendant in a patent action, Sandoz Canada Inc., brought a motion to compel the Plaintiffs, Boehringer Ingelheim (Canada) Ltd and Boehringer Ingelheim International GMBH, to answer questions refused on the discovery of inventors under Rule 237(4) of the Federal Courts Rules (the “Rules”).

Intellectual Property

Case summary: Permissible variations of a registered trademark

  • November 01, 2023
  • Julianna Felendzer

The Respondent initiated a summary cancellation proceeding under section 45 of the Trademarks Act, RSC 1985 c T-13 (the “TMA”) against the Applicant (“NBCL”) for their registered mark “NORTH BREWING.” The Registrar of Trademarks sent the cancellation notice of NBCL’s registered mark on May 31, 2021.

Intellectual Property

Assessment Officers assess costs, but cannot award costs

  • October 31, 2023
  • Will Boyer

In a 2021 trial decision, two BMS patents were found to be valid and infringed by generic products to be made and sold by Pharmascience and Sandoz. In the subsequent costs decision, the Court declined to fix costs in a lump sum amount, and instead awarded costs at the upper end of Column V of Tariff B to be determined on an assessment.

Intellectual Property

Case summary: Federal Court allows extension of time to serve notice of inter partes testing and to conduct testing, opposing party compensated for financial prejudice

  • October 31, 2023
  • Jenny Thistle and Tessa Clarke (Articling Student)

In this case, the Defendants (JAMP) successfully brought a motion for an extension of time to serve notice and conduct inter partes testing in the context of two proceedings commenced by the Plaintiffs (GILEAD) pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations.

Intellectual Property